Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: A nationwide study from Iceland

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)671-672
Number of pages2
JournalAnnals of the Rheumatic Diseases
Volume80
Issue number5
DOIs
Publication statusPublished - 5 Jan 2021

Other keywords

  • Antirheumatic Agents/therapeutic use
  • COVID-19
  • COVID-19/complications
  • Hospitalization/statistics & numerical data
  • Humans
  • Hypoxia/virology
  • Iceland/epidemiology
  • Methotrexate/therapeutic use
  • Prevalence
  • Rheumatic Diseases/drug therapy
  • SARS-CoV-2
  • biological therapy
  • epidemiology
  • methotrexate
  • tumor necrosis factors

Cite this